Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of “Moderate Buy” by Brokerages

Oncolytics Biotech Inc. (NASDAQ:ONCY) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $5.00.

ONCY has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Wednesday, October 8th. Lake Street Capital initiated coverage on Oncolytics Biotech in a research report on Wednesday, August 13th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Wall Street Zen raised Oncolytics Biotech from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently raised its stake in Oncolytics Biotech stock. Seeds Investor LLC grew its stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) by 17.8% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 223,767 shares of the company’s stock after buying an additional 33,826 shares during the period. Seeds Investor LLC owned approximately 0.23% of Oncolytics Biotech worth $173,000 as of its most recent filing with the SEC. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Stock Performance

ONCY opened at $1.18 on Monday. The firm has a market cap of $118.42 million, a P/E ratio of -4.37 and a beta of 1.24. The business has a 50 day moving average price of $1.19 and a 200 day moving average price of $0.87. Oncolytics Biotech has a twelve month low of $0.33 and a twelve month high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. As a group, analysts anticipate that Oncolytics Biotech will post -0.28 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.